Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.58 |
| ▸ | MAPT | P10636 | 5/20 | 0.58 |
| ▸ | HTT | P42858 | 4/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 4/20 | 0.57 |
| ▸ | RAB9A | P51151 | 4/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.56 |
| ▸ | GRIK1 | P39086 | 3/20 | 0.53 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.53 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.52 |
| ▸ | RELA | Q04206 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30104934 | 0.83 | MEN1 (0.53) | MEN1KMT2AMAPTHTTLMNA | |
| SCHEMBL23831754 | 0.83 | MEN1 (0.53) | MEN1KMT2AMAPTHTTLMNA | |
| SCHEMBL6436290 | 0.82 | KMT2A (0.68) | MEN1KMT2AMAPTHTTLMNA | |
| SCHEMBL19707566 | 0.82 | GAA (0.65) | MEN1KMT2AMAPTHTTLMNA | |
| SCHEMBL11846997 | 0.80 | RAB9A (0.73) | MEN1KMT2AHTTLMNANPC1 | |
| SCHEMBL6434716 | 0.80 | KDR (0.67) | MEN1KMT2AMAPTHTTRAB9A | |
| SCHEMBL6431252 | 0.79 | RAB9A (0.66) | MEN1KMT2AMAPTHTTNPC1 | |
| SCHEMBL30995905 | 0.78 | CA12 (0.60) | MEN1KMT2AMAPTHTTLMNA | |
| SCHEMBL12218028 | 0.78 | CA12 (0.60) | MEN1KMT2AMAPTHTTLMNA | |
| SCHEMBL6433829 | 0.78 | MEN1 (0.71) | MEN1KMT2AMAPTHTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050080112-A1 | Compounds for use in disorders associated with mast cell or basophil acitvity | POSEIDON PHARMACEUTICALS A/S (DK) | 2005-04-14 | — | — | US | claimed |
| EP-1514867-A2 | Substituted phenyl derivatives, their preparation and use | NeuroSearch A/S (DK) | 2005-03-16 | — | — | EP | claimed |
| US-20020037905-A1 | Substituted phenyl derivatives, their preparation and use | ANIONA APS (DK) | 2002-03-28 | — | — | US | claimed |
| US-20020032210-A1 | Substituted phenyl derivatives, their preparation and use | ANIONA APS (DK) | 2002-03-14 | — | — | US | claimed |
| EP-1514867-A2 | Substituted phenyl derivatives, their preparation and use | NeuroSearch A/S (DK) | 2005-03-16 | — | — | EP | disclosed |
| US-6706749-B2 | CHLORIDE CHANNEL BLOCKERS; USEFUL IN THE TREATMENT OF SICKLE CELL ANAEMIA, BRAIN EDEMA FOLLOWING ISCAEMIA OR TUMORS, DIARRHEA, HYPERTENSION, BONE METABOLIC DISORDERS, OSTEOCLAST ASSOCIATED DISODERS; SUBSTITUTED BIPHENYL CONTAINING NITROGEN | NEUROSEARCH A/S (DK) | 2004-03-16 | — | — | US | disclosed |
| US-6696475-B2 | N-PHENYL-N'-(2-CARBOXYPHENYL) UREA, FOR EXAMPLE; CHLORIDE CHANNEL BLOCKERS; SUCH AS FOR TREATING BONE METABOLIC DISORDERS | NEUROSEARCH A/S (DK) | 2004-02-24 | — | — | US | disclosed |
| US-20020037905-A1 | Substituted phenyl derivatives, their preparation and use | ANIONA APS (DK) | 2002-03-28 | — | — | US | disclosed |
| US-20020032210-A1 | Substituted phenyl derivatives, their preparation and use | ANIONA APS (DK) | 2002-03-14 | — | — | US | disclosed |
| EP-1123274-A1 | SUBSTITUTED PHENYL DERIVATIVES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 2001-08-16 | — | — | EP | disclosed |
| WO-2000024707-A1 | SUBSTITUTED PHENYL DERIVATIVES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 2000-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032210-A1 | Substituted phenyl derivatives, their preparation and use | KCNB1, KCNB2, KCNH2 | MEN1 2987/4885KMT2A 2188/4885MAPT 3324/4885 |
| US-20020037905-A1 | Substituted phenyl derivatives, their preparation and use | KCNB1, KCNH2, KCNJ2 | MEN1 2384/4885KMT2A 2286/4885MAPT 3787/4885 |
| US-20050080112-A1 | Compounds for use in disorders associated with mast cell or basophil acitvity | CPA3, HNMT, CMA1 | MEN1 903/4885KMT2A 1345/4885MAPT 1603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.